Preclinical biomarkers in Alzheimer disease: a sum greater than the parts.

@article{Resnick2014PreclinicalBI,
  title={Preclinical biomarkers in Alzheimer disease: a sum greater than the parts.},
  author={Susan M. Resnick},
  journal={JAMA neurology},
  year={2014},
  volume={71 11},
  pages={1357-8}
}
As clinical trials move to earlier stages of disease and focus on cognitively normal (CN) individuals with positive biomarkers of Alzheimer disease (AD) (eg, β-amyloid [Aβ]), it is critical to determine the relationship between these biomarkers and cognitive change. It is especially important to determine whether this cognitive change varies by biomarker status and whether sufficient cognitive change occurs to provide clinically meaningful outcomes during short follow-up intervals. For example… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 11 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 10 references

Similar Papers

Loading similar papers…